Clinical Report: Worldwide Research Patterns and New Developments in Intratumoral Microbiota's Role in Cancer Immunotherapy

Overview

This study systematically maps the emerging field of intratumoral microbiota in cancer immunotherapy, highlighting significant growth in research output and evolving hotspots.

Background

Intratumoral microbiota are increasingly recognized as vital components of the tumor microenvironment, influencing immune responses and therapeutic outcomes in cancer immunotherapy. Research in this area remains fragmented across various disciplines.

Data Highlights

Key Findings

• Research on intratumoral microbiota has grown exponentially since 2017, with a CAGR of 63.1%.
• China leads in publication output, while the United States has a central role in citations and collaborations.
• The term 'intratumoral microbiota' was the most frequent keyword, indicating a focus on this area.
• Research hotspots have shifted from gut microbiota and immune mechanisms to immunotherapy resistance and microbiota-targeted interventions.

Clinical Implications

The findings suggest that understanding intratumoral microbiota could enhance the prediction of responses to immunotherapy. Clinicians should consider the evolving role of microbiota in shaping therapeutic strategies and patient outcomes.

Conclusion

Future studies should focus on standardization and validation to facilitate clinical applications.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Functional convergence amid taxonomic variability in gut microbiome–immune checkpoint inhibitor research: a bibliometric and mechanistic synthesis
2. Frontiers in Immunology, 2026 -- The relationship between Gut Microbiota and Cancer Immune Response and Immunotherapy
3. Frontiers in Immunology, 2026 -- The intratumoral microbiome: a review of the tumor microenvironment’s fourth axis shaping anti-tumor immunity, cancer prognosis, and therapeutic response
4. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols - PMC, 2025
5. Frontiers in Oncology — T cell-mediated immune function in gastric cancer: a bibliometric overview of the last 20 years (2006-2025)
6. The tumor microbiome and cancer immunotherapy: A systematic review of a new frontier beyond the gut
7. Cancer microbiota: a focus on tumor-resident bacteria | EMBO Reports | Springer Nature Link
8. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols - PMC